BACKGROUND: Management of frailty is the cornerstone of geriatric medicine, but there remains a need to identify biomarkers that can predict early death, and thereby lead to effective clinical interventions. We aimed to study the combination of C-reactive protein (CRP), albumin, gamma-glutamyl transferase (GGT), and HDL to predict mortality. METHODS: A total of 44,457 persons aged 50+ whose levels of CRP, albumin, GGT, and HDL were measured at baseline were selected from the Swedish Apolipoprotein MOrtality RISk (AMORIS) study. A mortality score, ranging from 0 to 4, was created by adding the number of markers with abnormal values according to the clinical cut-off (CRP > 10 mg/L, albumin < 35 mg/L, GGT > 36 kU/L, HDL < 1.04 mmol/L). Mortality was studied with multivariate Cox proportional hazards models. RESULTS: 2,245 persons died from cancer, 3,276 from circulatory disease, and 1,860 from other causes. There was a positive trend between mortality score and all-cause mortality as well as cancer and circulatory disease-specific death (e.g. HR for all-cause mortality: 1.39 (95%CI: 1.32-1.46), 2.04 (1.89-2.21), and 3.36 (2.87-3.93), for score=1, 2, and 3+, compared to score=0). Among cancer patients with no other co-morbidities (n=1,955), there was a positive trend between the score and mortality (HR: 1.24 (95%CI: 1.0.-1.49), 2.38 (95%CI: 1.76-3.22), and 5.47 (95%CI: 2.98-10.03) for score=1, 2, and 3+ compared to score=0). CONCLUSIONS: By combining biomarkers of different mechanisms contributing to patient frailty, we found a strong marker for mortality in persons aged 50+. Elevated risks among cancer patients with no other co-morbidities prior to biomarker assessment call for validation in other cohorts and testing of different combinations and cut-offs than those used here, in order to aid decision-making in treatment of older cancer patients.
BACKGROUND: Management of frailty is the cornerstone of geriatric medicine, but there remains a need to identify biomarkers that can predict early death, and thereby lead to effective clinical interventions. We aimed to study the combination of C-reactive protein (CRP), albumin, gamma-glutamyl transferase (GGT), and HDL to predict mortality. METHODS: A total of 44,457 persons aged 50+ whose levels of CRP, albumin, GGT, and HDL were measured at baseline were selected from the Swedish Apolipoprotein MOrtality RISk (AMORIS) study. A mortality score, ranging from 0 to 4, was created by adding the number of markers with abnormal values according to the clinical cut-off (CRP > 10 mg/L, albumin < 35 mg/L, GGT > 36 kU/L, HDL < 1.04 mmol/L). Mortality was studied with multivariate Cox proportional hazards models. RESULTS: 2,245 persons died from cancer, 3,276 from circulatory disease, and 1,860 from other causes. There was a positive trend between mortality score and all-cause mortality as well as cancer and circulatory disease-specific death (e.g. HR for all-cause mortality: 1.39 (95%CI: 1.32-1.46), 2.04 (1.89-2.21), and 3.36 (2.87-3.93), for score=1, 2, and 3+, compared to score=0). Among cancerpatients with no other co-morbidities (n=1,955), there was a positive trend between the score and mortality (HR: 1.24 (95%CI: 1.0.-1.49), 2.38 (95%CI: 1.76-3.22), and 5.47 (95%CI: 2.98-10.03) for score=1, 2, and 3+ compared to score=0). CONCLUSIONS: By combining biomarkers of different mechanisms contributing to patient frailty, we found a strong marker for mortality in persons aged 50+. Elevated risks among cancerpatients with no other co-morbidities prior to biomarker assessment call for validation in other cohorts and testing of different combinations and cut-offs than those used here, in order to aid decision-making in treatment of older cancerpatients.
Authors: A G Pallis; C Fortpied; U Wedding; M C Van Nes; B Penninckx; A Ring; D Lacombe; S Monfardini; P Scalliet; H Wildiers Journal: Eur J Cancer Date: 2010-03-12 Impact factor: 9.162
Authors: David G Le Couteur; Fiona M Blyth; Helen M Creasey; David J Handelsman; Vasi Naganathan; Philip N Sambrook; Markus J Seibel; Louise M Waite; Robert G Cumming Journal: J Gerontol A Biol Sci Med Sci Date: 2010-05-24 Impact factor: 6.053
Authors: Francesco Landi; Andrea Russo; Marco Pahor; Ettore Capoluongo; Rosa Liperoti; Matteo Cesari; Roberto Bernabei; Graziano Onder Journal: Gerontology Date: 2007-11-15 Impact factor: 5.140
Authors: Alexander M Strasak; Kilian Rapp; Larry J Brant; Wolfgang Hilbe; Martin Gregory; Willi Oberaigner; Elfriede Ruttmann; Hans Concin; Günter Diem; Karl P Pfeiffer; Hanno Ulmer Journal: Cancer Res Date: 2008-05-15 Impact factor: 12.701
Authors: Andrew B C Crumley; Robert C Stuart; Margaret McKernan; Alexander C McDonald; Donald C McMillan Journal: J Gastroenterol Hepatol Date: 2007-07-20 Impact factor: 4.029
Authors: Ruth E Hubbard; M Sinead O'Mahony; George M Savva; Brian L Calver; Ken W Woodhouse Journal: J Cell Mol Med Date: 2009-03-06 Impact factor: 5.310
Authors: Sok-Ja Janket; Alison E Baird; Judith A Jones; Elizabeth A Jackson; Markku Surakka; Wen Tao; Jukka H Meurman; Thomas E Van Dyke Journal: J Clin Periodontol Date: 2013-12-10 Impact factor: 8.728
Authors: Pål Hasvold; Marcus Thuresson; Johan Sundström; Niklas Hammar; Sverre E Kjeldsen; Gunnar Johansson; Ingar Holme; Johan Bodegård Journal: Clin Drug Investig Date: 2016-03 Impact factor: 2.859
Authors: Leavitt Morrison; Jari A Laukkanen; Kimmo Ronkainen; Sudhir Kurl; Jussi Kauhanen; Adetunji T Toriola Journal: BMC Cancer Date: 2016-02-10 Impact factor: 4.430
Authors: Otavio T Ranzani; Fernando Godinho Zampieri; Daniel Neves Forte; Luciano Cesar Pontes Azevedo; Marcelo Park Journal: PLoS One Date: 2013-03-12 Impact factor: 3.240